TY - JOUR
AU - Henry, S.
AB - Lifetime cancer potency of alfatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day)−1 for individuals negative for hepatitis B and 230 (mg/kg/day)−1 for individuals positive for hepatitis B.
TI - Risk Assessment for Aflatoxin: An Evaluation Based on the Multistage Model
JF - Risk Analysis
DO - 10.1111/j.1539-6924.1993.tb01325.x
DA - 1993-12-01
UR - https://www.deepdyve.com/lp/wiley/risk-assessment-for-aflatoxin-an-evaluation-based-on-the-multistage-7FKV40JYHo
SP - 637
VL - 13
IS - 6
DP - DeepDyve
ER -